{"id":"imatinib-im","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Nausea"},{"rate":"30-40%","effect":"Vomiting"},{"rate":"40-50%","effect":"Diarrhea"},{"rate":"60-70%","effect":"Edema (fluid retention)"},{"rate":"25-35%","effect":"Muscle cramps"},{"rate":"25-35%","effect":"Rash"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-40%","effect":"Myelosuppression (anemia, thrombocytopenia, neutropenia)"},{"rate":"5-10%","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL941","moleculeType":"Small molecule","molecularWeight":"493.62"},"_dailymed":{"setId":"a4e409f7-20b4-4c80-8a6a-f95995ffad78","title":"IMATINIB MESYLATE TABLET, FILM COATED [AUROBINDO PHARMA LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imatinib selectively inhibits the constitutively active BCR-ABL tyrosine kinase that results from the Philadelphia chromosome translocation in chronic myeloid leukemia (CML). By blocking this kinase, it prevents the downstream signaling that drives uncontrolled myeloid cell proliferation. The drug also inhibits KIT and PDGFRA kinases, making it effective in gastrointestinal stromal tumors (GISTs) driven by these mutations.","oneSentence":"Imatinib is a tyrosine kinase inhibitor that blocks the BCR-ABL fusion protein and other kinases, preventing abnormal cell proliferation in chronic myeloid leukemia and gastrointestinal stromal tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:35:28.203Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML), Philadelphia chromosome positive"},{"name":"Gastrointestinal stromal tumor (GIST), KIT-positive"},{"name":"Acute lymphoblastic leukemia (ALL), Philadelphia chromosome positive"}]},"trialDetails":[{"nctId":"NCT02891395","phase":"PHASE2","title":"Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2012-12-24","conditions":"Graft Versus Host Disease","enrollment":65},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT06628739","phase":"","title":"Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2017-07-01","conditions":"Gastrointestinal Stromal Tumor, Malignant","enrollment":168},{"nctId":"NCT04276415","phase":"PHASE1","title":"DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2020-05-08","conditions":"Gastrointestinal Stromal Tumors","enrollment":34},{"nctId":"NCT01025505","phase":"PHASE2","title":"Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2012-06","conditions":"Treatment, Stem Cell Transplantation","enrollment":40},{"nctId":"NCT04041674","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT01827930","phase":"PHASE3","title":"Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response","status":"TERMINATED","sponsor":"Institut Bergonié","startDate":"2009-07","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":68},{"nctId":"NCT02538926","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2018-07-01","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT01429610","phase":"PHASE2","title":"Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2011-11","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":78},{"nctId":"NCT00882206","phase":"PHASE2","title":"Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2009-04","conditions":"Leukemia, Lymphoma","enrollment":15},{"nctId":"NCT00677092","phase":"PHASE2","title":"Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-12","conditions":"Nephrogenic Systemic Fibrosis","enrollment":12},{"nctId":"NCT00858806","phase":"PHASE2","title":"Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2008-04","conditions":"Chronic Myeloid Leukemia","enrollment":78},{"nctId":"NCT00415909","phase":"PHASE2","title":"TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Chronic Myelogenous Leukemia","enrollment":3},{"nctId":"NCT00022737","phase":"PHASE3","title":"Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT01564836","phase":"NA","title":"Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2010-06","conditions":"Chronic Myeloid Leukemia, Imatinib, Complete Molecular Response","enrollment":50},{"nctId":"NCT00049569","phase":"NA","title":"Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-01","conditions":"L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Non-T, Non-B Childhood Acute Lymphoblastic Leukemia","enrollment":126},{"nctId":"NCT01227135","phase":"PHASE2","title":"Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia","status":"UNKNOWN","sponsor":"Lynn McMahon","startDate":"2010-03","conditions":"Leukemia","enrollment":66},{"nctId":"NCT00146913","phase":"PHASE2","title":"AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2004-03","conditions":"Chronic Myeloid Leukemia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":373,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gleevec"],"phase":"marketed","status":"active","brandName":"imatinib (IM)","genericName":"imatinib (IM)","companyName":"First Affiliated Hospital, Sun Yat-Sen University","companyId":"first-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imatinib is a tyrosine kinase inhibitor that blocks the BCR-ABL fusion protein and other kinases, preventing abnormal cell proliferation in chronic myeloid leukemia and gastrointestinal stromal tumors. Used for Chronic myeloid leukemia (CML), Philadelphia chromosome positive, Gastrointestinal stromal tumor (GIST), KIT-positive, Acute lymphoblastic leukemia (ALL), Philadelphia chromosome positive.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}